Financhill
Sell
40

BIO Quote, Financials, Valuation and Earnings

Last price:
$238.88
Seasonality move :
0.08%
Day range:
$238.09 - $243.15
52-week range:
$215.38 - $387.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.64x
P/B ratio:
0.97x
Volume:
244.7K
Avg. volume:
376.1K
1-year change:
-13.93%
Market cap:
$6.5B
Revenue:
$2.6B
EPS (TTM):
-$76.20

Analysts' Opinion

  • Consensus Rating
    Bio-Rad Laboratories has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $318.67, Bio-Rad Laboratories has an estimated upside of 33.51% from its current price of $238.68.
  • Price Target Downside
    According to analysts, the lowest downside price target is $260.00 representing 100% downside risk from its current price of $238.68.

Fair Value

  • According to the consensus of 4 analysts, Bio-Rad Laboratories has 33.51% upside to fair value with a price target of $318.67 per share.

BIO vs. S&P 500

  • Over the past 5 trading days, Bio-Rad Laboratories has overperformed the S&P 500 by 1.4% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Bio-Rad Laboratories does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Bio-Rad Laboratories revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Bio-Rad Laboratories reported revenues of $585.4M.

Earnings Growth

  • Bio-Rad Laboratories earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Bio-Rad Laboratories reported earnings per share of $2.29.
Enterprise value:
6B
EV / Invested capital:
0.77x
Price / LTM sales:
2.64x
EV / EBIT:
--
EV / Revenue:
2.38x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
18.18x
Price / Operating cash flow:
20.18x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$1.4B
Return On Assets:
-20.89%
Net Income Margin (TTM):
-85.17%
Return On Equity:
-29.59%
Return On Invested Capital:
-25.43%
Operating Margin:
4.05%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Income Statement
Revenue $2.8B $2.6B $2.5B $610.8M $585.4M
Gross Profit $1.5B $1.4B $1.4B $325.9M $306M
Operating Income $390.6M $320.5M $248M $44.6M $23.7M
EBITDA -$65.5M -$247.1M -$2.5B $540.5M $133.5M
Diluted EPS -$6.43 -$10.36 -$76.20 $13.45 $2.29
Period Ending 2021-03-31 2022-03-31 2023-03-31 2024-03-31 2025-03-31
Balance Sheet
Current Assets $2.2B $3.3B $3.3B $3.1B $3B
Total Assets $13.9B $14.4B $13.7B $12.6B $9.5B
Current Liabilities $609.9M $648.3M $589.6M $466.2M $506.6M
Total Liabilities $3.3B $4.2B $3.9B $3.6B $2.8B
Total Equity $10.6B $10.2B $9.8B $9.1B $6.7B
Total Debt $1.2M $1.2B $1.2B $1.2B $1.2B
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Cash Flow Statement
Cash Flow Operations $242M $346.6M $515.3M $69.8M $129.9M
Cash From Investing -$361.9M $47.6M -$114.2M -$43.1M $2.9M
Cash From Financing -$212.4M -$429.9M -$316.5M -- -$97.7M
Free Cash Flow $125.1M $185.4M $332.1M $29.6M $95.5M
BIO
Sector
Market Cap
$6.5B
$33.9M
Price % of 52-Week High
61.52%
43.63%
Dividend Yield
0%
0%
Shareholder Yield
4.46%
-0.68%
1-Year Price Total Return
-13.93%
-41.67%
Beta (5-Year)
0.999
0.660
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Buy
Level $238.11
200-day SMA
Sell
Level $310.98
Bollinger Bands (100)
Sell
Level 242.07 - 335.63
Chaikin Money Flow
Buy
Level 24.9M
20-day SMA
Sell
Level $241.71
Relative Strength Index (RSI14)
Sell
Level 47.01
ADX Line
Buy
Level 15.92
Williams %R
Neutral
Level -68.5751
50-day SMA
Sell
Level $245.91
MACD (12, 26)
Sell
Level -3.34
25-day Aroon Oscillator
Buy
Level 44
On Balance Volume
Neutral
Level 21.4M

Financial Scores

Hold
Altman Z-Score (Annual)
Level (2.8785)
Sell
CA Score (Annual)
Level (-0.378)
Buy
Beneish M-Score (Annual)
Level (-3.6873)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-0.345)
Buy
Piotroski F Score (Annual)
Level (6)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (6)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Stock Forecast FAQ

In the current month, BIO has received 2 Buy ratings 2 Hold ratings, and 0 Sell ratings. The BIO average analyst price target in the past 3 months is $318.67.

  • Where Will Bio-Rad Laboratories Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Bio-Rad Laboratories share price will rise to $318.67 per share over the next 12 months.

  • What Do Analysts Say About Bio-Rad Laboratories?

    Analysts are divided on their view about Bio-Rad Laboratories share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bio-Rad Laboratories is a Sell and believe this share price will drop from its current level to $260.00.

  • What Is Bio-Rad Laboratories's Price Target?

    The price target for Bio-Rad Laboratories over the next 1-year time period is forecast to be $318.67 according to 4 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.

  • Is BIO A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Bio-Rad Laboratories is a Leans Bullish. 2 of 4 analysts rate the stock a Leans Bullish at this time.

  • How Can I Buy Shares Of BIO?

    You can purchase shares of Bio-Rad Laboratories via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bio-Rad Laboratories shares.

  • What Is The Bio-Rad Laboratories Share Price Today?

    Bio-Rad Laboratories was last trading at $238.88 per share. This represents the most recent stock quote for Bio-Rad Laboratories. Yesterday, Bio-Rad Laboratories closed at $238.68 per share.

  • How To Buy Bio-Rad Laboratories Stock Online?

    In order to purchase Bio-Rad Laboratories stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Spotify a Millionaire-Maker Stock?
Is Spotify a Millionaire-Maker Stock?

Spotify (NYSE:SPOT) may seem like an expensive proposition trading closer…

What Is a Millionaire-Maker Stock?
What Is a Millionaire-Maker Stock?

From time to time, investors will run across the term…

5 Investors to Follow Other Than Warren Buffett
5 Investors to Follow Other Than Warren Buffett

There is no doubt that Warren Buffett is one of…

Stock Ideas

Buy
68
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Buy
61
Is NVDA Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 40x

Alerts

Buy
60
RGC alert for May 10

Regencell Bioscience Holdings [RGC] is up 79.25% over the past day.

Buy
97
NGVC alert for May 10

Natural Grocers by Vitamin Cottage [NGVC] is up 30.26% over the past day.

Sell
38
ONTO alert for May 10

Onto Innovation [ONTO] is down 30.17% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock